Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
High use of hydrochlorothiazide (HCTZ) appears to significantly increase the risk of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), suggests a recent study. Use of other diuretic and antihypertensive medications does not appear to be linked to NMSC.
Taking the oral extract product of the fern Polypodium leucotomos (PLE) on top of the standard topical hydroquinone cream and sunscreen reduces the severity of melasma to a greater extent compared with the standard treatment alone in Asian patients, a pilot study has shown.
Severe malnutrition appears to negatively affect quality of life (QoL) in patients with systemic sclerosis, which underscores the importance of routine and standardized nutritional screenings as well as appropriate and multimodal interventions, a recent study has shown.
Autologous fat transfer appears to be an effective approach for soft-tissue deformities during facial reconstruction, with high rates of patient satisfaction and low rates of complications, a recent study has shown.
A recent study has shown that 5-fluorouracil is significantly more effective than imiquimod in the short-term prevention of subsequent actinic keratoses (AKs).
Optimal delivery or duration of systemic corticosteroids in atopic dermatitis (AD) cannot be established as there is not enough strong evidence in existing literature, suggests a recent study.
New drug applications approved by US FDA as of 16 - 31 March 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvalsmay have occurred since the original approval date.
Special Reports
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Eczema (atopic dermatitis) is a chronic inflammatory skin disease that
can present in many different forms. However, it is principally
characterized by dry skin, intense itching, and the presence of
inflammatory skin lesions. [J Eur Acad Dermatol Venereol
2016;30:604-618; N Engl J Med 2008;358:1483-1494; Lancet
2016;387:1109-1122]
At the 42nd Annual Dermatology Conference 2017 held recently in Kuala Lumpur, Professor Michael J. Cork spoke on the interaction between genetic and environmental factors as a primary event in the development of atopic dermatitis (AD) and highlighted the role of topical calcineurin inhibitors (TCIs) in the management of AD.
The prevalence of atopic dermatitis (AD) in industrialized countries has increased exponentially over the past three decades, currently affecting 15 to 30% of children and up to 10% of adults.1 At the recent official launch event of pimecrolimus (Elidel®, Meda Healthcare Sdn. Bhd.) held at Le Méridien Kuala Lumpur, Professor Thomas Luger provided insights on the pathophysiology of AD and the role of topical calcineurin inhibitors (TCIs) in the management of AD.
CANESTEN HC – Clotrimazole 1% w/w and hydrocortisone 1% w/w cream – Bayer
All patients with acne are potentially at risk of scarring. Professor Goh Chee Leok addresses this issue by focussing on preventing the development of scars in his talk at the 41st Annual Meeting of the Dermatological Society of Malaysia held in Kuching, Sarawak.
During the 41st Annual Dermatology Conference held in Kuching, Sarawak, Professor Steven R. Feldman updated the participants on the latest in topical treatment of psoriasis. Highlights from the presentation are summarized below.
Conference Reports
Continued treatment with the anti-interleukin (IL)-23 monoclonal antibody guselkumab generated high efficacy response rates in patients with moderate-to-severe plaque psoriasis, according to findings from the ongoing phase III VOYAGE 2* trial presented at the 2018 American Academy of Dermatology Annual Meeting (AAD 2018) held in San Diego, California, US.
The approved psoriasis therapy ustekinumab also reduces aortic vascular inflammation, along with improved psoriasis severity, compared with placebo in patients with moderate-to-severe psoriasis, according to the VIP-U* study presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, US.
The humanized IgG1 monoclonal antibody risankizumab cleared plaque psoriasis better than ustekinumab and placebo in two phase III head-to-head studies. Risankizumab also appeared to be superior to ustekinumab or placebo in many endpoints.
